Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kooistra, M.
Right arrow Articles by Marx, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kooistra, M.
Right arrow Articles by Marx, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrology Dialysis Transplantation, Vol 12, Issue 5 879-883, Copyright © 1997 by Oxford University Press

ORIGINAL ARTICLES

The management of iron metabolism in recombinant human erythropoietin treated dialysis patients by Dutch nephrologists

M Kooistra and J Marx
Foundation for Home Dialysis Mid-West Netherlands, Utrecht, The Netherlands; Department of Internal Medicine, University Hospital, Utrecht, The Netherlands; Eijkman-Winkler Institute, University of Utrecht, Utrecht, The Netherlands; Correspondence to MP Kooistra, Stichting Thuisdialyse Midden-West Nederland, Brennerbaan 130, 3524 BN Utrecht, The Netherlands

Background. The regulation of iron metabolism is an important aspect of r-HuEPO treatment. Method. All Dutch nephrologists involved in dialysis were asked to complete a questionnaire about iron metabolism management in dialysis patients. Results. The response rate was 68%, covering 83% of all Dutch dialysis units. Iron status is assessed before starting r-HuEPO by 96% of the respondents, but only 58% waits for the results. Serum ferritin is determined by 98%, MCV by 77%, transferrin saturation by 44%, the percentage hypochromic red blood cells by 6%, bone marrow iron staining by 4%, and serum transferrin receptors by 0%. Serum ferritin is considered to be the most important parameter by 48%, transferrin saturation by 37%, percentage hypochromic red blood cells and serum transferrin receptors by 0%. Of the respondents, 17% determines iron status twice a year, 13% three times, 54% four times, 4% six times, 4% eight times, and 8% twelve times. Iron is given to all patients by 40% of the nephrologists, 60% prescribes iron on indication. Oral substitution is preferred by 90%, but 27% incidentally prescribes intravenous iron without testing the effects of oral iron. Of all haemodialysis patients on r-HuEPO, 16% (SD 18, median 10) receives no iron substitution, 65% (± 28, 73) oral iron and 19% (± 28, 6) intravenous iron. Of all CAPD patients, 22% (± 24, 16) receives no iron substitution, 77% (± 24, 81) oral iron, and 1% (± 2, 0) intravenous iron. Conclusion. There is no communis opinio among Dutch nephrologists on the frequency of iron status assessment, the choice of parameters, the indications for iron substitution, or the decision between oral or intravenous substitution. Keywords: anaemia; erythropoietin; iron metabolism; dialysis
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.